Valproate (Epilepsy)

Microcephaly / Small head circumference for gestational age

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6416
R17615
Pennell (Valproate), 2012 Microcephaly at birth (head circumference < 3 percentile) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 1.27 [0.34;4.83] C 4/38   6/71 10 38
ref
S371
R18374
Kini (Valproate) (Controls unexposed, sick), 2006 Head circumference in children aged between 6 months and 16 years <3rd centile during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 1.66 [0.46;5.96] C 5/63   5/101 10 63
ref
S6435
R17691
Battino (Valproate), 1999 Small head circumferences (at birth < 10th percentile) throughout pregnancy prospective cohort unexposed, sick Adjustment: No 0.68 [0.14;3.26] C 4/57   3/30 7 57
ref
S6777
R19137
Díaz-Romero (Valproate), 1999 Head circumference <2 SD at birth (measured by a physician and correlated with sex and with gestational age) during pregnancy (anytime or not specified) cohort unexposed, sick Adjustment: No 0.79 [0.01;44.65] C 0/10   0/8 0 10
ref
S5702
R19483
Dravet (Valproate), 1992 Isolated microcephaly at birth (head circumference >2 SD lower than those given in the reference tables adjusted for gestational age at birth) 1st trimester prospective cohort unexposed, sick Adjustment: No 3.12 [0.34;28.74] C 6/31   1/14 7 31
ref
Total 5 studies 1.31 [0.63;2.74] 34 199
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pennell (Valproate), 2012Pennell, 2012 1 1.27[0.34; 4.83]103831%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Kini (Valproate) (Controls unexposed, sick), 2006Kini, 2006 2 1.66[0.46; 5.96]106333%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: unclearROB mesure: moderateROB reporting: moderate Battino (Valproate), 1999Battino, 1999 3 0.68[0.14; 3.26]75722%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: moderate Díaz-Romero (Valproate), 1999Díaz-Romero, 1999 4 0.79[0.01; 44.65]0103%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Dravet (Valproate), 1992Dravet, 1992 5 3.12[0.34; 28.74]73111%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (5 studies) I2 = 0% 1.31[0.63; 2.74]341990.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate; 2: Valproate) (Controls unexposed, sick; 3: Valproate; 4: Valproate; 5: Valproate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.31[0.63; 2.74]341990%NAPennell (Valproate), 2012 Kini (Valproate) (Controls unexposed, sick), 2006 Battino (Valproate), 1999 Díaz-Romero (Valproate), 1999 Dravet (Valproate), 1992 5 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.33[0.55; 3.22]241610%NAKini (Valproate) (Controls unexposed, sick), 2006 Battino (Valproate), 1999 Díaz-Romero (Valproate), 1999 Dravet (Valproate), 1992 4 exposed to other treatment, sickexposed to other treatment, sick 1.27[0.34; 4.83]1038 -NAPennell (Valproate), 2012 1 Tags Adjustment   - No  - No 1.31[0.63; 2.74]341990%NAPennell (Valproate), 2012 Kini (Valproate) (Controls unexposed, sick), 2006 Battino (Valproate), 1999 Díaz-Romero (Valproate), 1999 Dravet (Valproate), 1992 5 All studiesAll studies 1.31[0.63; 2.74]341990%NAPennell (Valproate), 2012 Kini (Valproate) (Controls unexposed, sick), 2006 Battino (Valproate), 1999 Díaz-Romero (Valproate), 1999 Dravet (Valproate), 1992 50.210.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.85.12.4710.000Pennell (Valproate), 2012Kini (Valproate) (Controls unexposed, sick), 2006Battino (Valproate), 1999Díaz-Romero (Valproate), 1999Dravet (Valproate), 1992

Asymetry test p-value = 0.9962 (by Egger's regression)

slope=0.2685 (0.7942); intercept=0.0048 (0.9454); t=0.0051; p=0.9962

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.33[0.55; 3.22]241610%NAKini (Valproate) (Controls unexposed, sick), 2006 Battino (Valproate), 1999 Díaz-Romero (Valproate), 1999 Dravet (Valproate), 1992 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.27[0.34; 4.83]1038 -NAPennell (Valproate), 2012 10.510.01.0